Gregoire Longchamp1, Sara Manzocchi-Besson2,3, Alban Longchamp4,5, Marc Righini2, Helia Robert-Ebadi2, Marc Blondon6. 1. Department of Visceral Surgery, Faculty of Medicine and Geneva University Hospitals, Geneva, Switzerland. 2. Division of Angiology and Haemostasis, Geneva University Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland. 3. Department of Vascular Surgery, Centre Hospitalier du Valais Romand de l'Hôpital du Valais (site de Sion), Sion, Switzerland. 4. Department of Vascular Surgery, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland. 5. Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland. 6. Division of Angiology and Haemostasis, Geneva University Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland. marc.blondon@hcuge.ch.
Abstract
BACKGROUND: COVID-19 appears to be associated with a high risk of venous thromboembolism (VTE). We aimed to systematically review and meta-analyze the risk of clinically relevant VTE in patients hospitalized for COVID-19. METHODS: This meta-analysis included original articles in English published from January 1st, 2020 to June 15th, 2020 in Pubmed/MEDLINE, Embase, Web of science, and Cochrane. Outcomes were major VTE, defined as any objectively diagnosed pulmonary embolism (PE) and/or proximal deep vein thrombosis (DVT). Primary analysis estimated the risk of VTE, stratified by acutely and critically ill inpatients. Secondary analyses explored the separate risk of proximal DVT and of PE; the risk of major VTE stratified by screening and by type of anticoagulation. RESULTS: In 33 studies (n = 4009 inpatients) with heterogeneous thrombotic risk factors, VTE incidence was 9% (95%CI 5-13%, I2 = 92.5) overall, and 21% (95%CI 14-28%, I2 = 87.6%) for patients hospitalized in the ICU. Proximal lower limb DVT incidence was 3% (95%CI 1-5%, I2 = 87.0%) and 8% (95%CI 3-14%, I2 = 87.6%), respectively. PE incidence was 8% (95%CI 4-13%, I2 = 92.1%) and 17% (95%CI 11-25%, I2 = 89.3%), respectively. Screening and absence of anticoagulation were associated with a higher VTE incidence. When restricting to medically ill inpatients, the VTE incidence was 2% (95%CI 0-6%). CONCLUSIONS: The risk of major VTE among COVID-19 inpatients is high but varies greatly with severity of the disease. These findings reinforce the need for the use of thromboprophylaxis in all COVID-19 inpatients and for clinical trials testing different thromboprophylaxis regimens in subgroups of COVID-19 inpatients. TRIAL REGISTRATION: The review protocol was registered in PROSPERO International Prospective Register of Systematic Reviews ( CRD42020193369 ).
BACKGROUND:COVID-19 appears to be associated with a high risk of venous thromboembolism (VTE). We aimed to systematically review and meta-analyze the risk of clinically relevant VTE in patients hospitalized for COVID-19. METHODS: This meta-analysis included original articles in English published from January 1st, 2020 to June 15th, 2020 in Pubmed/MEDLINE, Embase, Web of science, and Cochrane. Outcomes were major VTE, defined as any objectively diagnosed pulmonary embolism (PE) and/or proximal deep vein thrombosis (DVT). Primary analysis estimated the risk of VTE, stratified by acutely and critically ill inpatients. Secondary analyses explored the separate risk of proximal DVT and of PE; the risk of major VTE stratified by screening and by type of anticoagulation. RESULTS: In 33 studies (n = 4009 inpatients) with heterogeneous thrombotic risk factors, VTE incidence was 9% (95%CI 5-13%, I2 = 92.5) overall, and 21% (95%CI 14-28%, I2 = 87.6%) for patients hospitalized in the ICU. Proximal lower limb DVT incidence was 3% (95%CI 1-5%, I2 = 87.0%) and 8% (95%CI 3-14%, I2 = 87.6%), respectively. PE incidence was 8% (95%CI 4-13%, I2 = 92.1%) and 17% (95%CI 11-25%, I2 = 89.3%), respectively. Screening and absence of anticoagulation were associated with a higher VTE incidence. When restricting to medically ill inpatients, the VTE incidence was 2% (95%CI 0-6%). CONCLUSIONS: The risk of major VTE among COVID-19 inpatients is high but varies greatly with severity of the disease. These findings reinforce the need for the use of thromboprophylaxis in all COVID-19 inpatients and for clinical trials testing different thromboprophylaxis regimens in subgroups of COVID-19 inpatients. TRIAL REGISTRATION: The review protocol was registered in PROSPERO International Prospective Register of Systematic Reviews ( CRD42020193369 ).
Authors: Anna Annunziata; Pasquale Imitazione; Giorgio Emanuele Polistina; Maurizia Lanza; Antonietta Coppola; Giuseppe Fiorentino Journal: Turk Thorac J Date: 2020-06-10
Authors: Marc Blondon; Alessandro Casini; Kara K Hoppe; Françoise Boehlen; Marc Righini; Nicholas L Smith Journal: Chest Date: 2016-06-01 Impact factor: 9.410
Authors: Zsuzsanna Varga; Andreas J Flammer; Peter Steiger; Martina Haberecker; Rea Andermatt; Annelies S Zinkernagel; Mandeep R Mehra; Reto A Schuepbach; Frank Ruschitzka; Holger Moch Journal: Lancet Date: 2020-04-21 Impact factor: 79.321
Authors: F A Klok; M J H A Kruip; N J M van der Meer; M S Arbous; D A M P J Gommers; K M Kant; F H J Kaptein; J van Paassen; M A M Stals; M V Huisman; H Endeman Journal: Thromb Res Date: 2020-04-10 Impact factor: 3.944
Authors: Hanny Al-Samkari; Rebecca S Karp Leaf; Walter H Dzik; Jonathan C T Carlson; Annemarie E Fogerty; Anem Waheed; Katayoon Goodarzi; Pavan K Bendapudi; Larissa Bornikova; Shruti Gupta; David E Leaf; David J Kuter; Rachel P Rosovsky Journal: Blood Date: 2020-07-23 Impact factor: 25.476
Authors: Marina Marchetti; Patricia Gomez-Rosas; Laura Russo; Sara Gamba; Eleonora Sanga; Cristina Verzeroli; Chiara Ambaglio; Francesca Schieppati; Francesco Restuccia; Ezio Bonanomi; Marco Rizzi; Stefano Fagiuoli; Andrea D'Alessio; Grigorios T Gerotziafas; Luca Lorini; Anna Falanga Journal: Front Cardiovasc Med Date: 2022-06-10
Authors: Ronaldo C Go; Themba Nyirenda; Maryam Bojarian; Davood K Hosseini; Mehek Rahim; Kevin Kim; Keith M Rose Journal: BMC Pulm Med Date: 2022-01-06 Impact factor: 3.317
Authors: Jose Maria Pereira de Godoy; Gleison Juliano da Silva Russeff; Carolina Hungaro Cunha; Debora Yuri Sato; Desirée Franccini Del Frari Silva; Henrique Jose Pereira de Godoy; Mariana Orate Menezes da Silva; Henrique Amorim; Marina Morães Lopes Soares; Maria de Fatima Guerreiro Godoy Journal: Phlebology Date: 2021-09-08 Impact factor: 1.740
Authors: Jacob Rosén; Maria Noreland; Karl Stattin; Miklós Lipcsey; Robert Frithiof; Andrei Malinovschi; Michael Hultström Journal: PLoS One Date: 2021-12-14 Impact factor: 3.240
Authors: Jose Maria Pereira de Godoy; Gleison Juliano da Silva Russeff; Carolina Hungaro Costa; Debora Yuri Sato; Desirée Franccini Del Frari Silva; Maria de Fatima Guerreiro Godoy; Henrique Jose Pereira de Godoy; Paulo César Espada Journal: Medicines (Basel) Date: 2021-11-29
Authors: Arthur Lieveld; M L A Heldeweg; J M Smit; M E Haaksma; L Veldhuis; R S Walburgh-Schmidt; J Twisk; P W B Nanayakkara; L Heunks; P R Tuinman Journal: J Crit Care Date: 2022-02-02 Impact factor: 4.298